-
Mashup Score: 4
Research is fundamental for effective cancer treatment to improve patient outcomes worldwide. On one hand, research has driven innovation and delivered treatments that have changed clinical practice for the better. On the other hand, lies concerning disparities. Previous literature outlines the
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 25Sex and authorship in global cancer research - 26 day(s) ago
Introduction Research is an essential pillar of cancer control and key in shaping regional cancer control agendas. Imbalances in science and technology in terms of lack of female participation have been well documented. However, there is little evidence about country-level female participation in cancer research. Methodology Through a complex filter, cancer research papers were identified and grouped by countries and sex of the first and last authors of each paper and analysed by the percentage of females in these positions alongside other parameters. Results Our analysis of 56 countries’ outputs, in 2009, revealed that females were the first authors in 37.2% and last authors in 23.3% of papers. In 2019, females were the first author in 41.6% and last author in 29.4% of papers. Females increased as first authors by 26%, and as last authors by 12% between these two time periods. The top performing countries in terms female/male parity for first or last authorship were in Eastern and Sou
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 4
Research is fundamental for effective cancer treatment to improve patient outcomes worldwide. On one hand, research has driven innovation and delivered treatments that have changed clinical practice for the better. On the other hand, lies concerning disparities. Previous literature outlines the
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 25Sex and authorship in global cancer research - 26 day(s) ago
Introduction Research is an essential pillar of cancer control and key in shaping regional cancer control agendas. Imbalances in science and technology in terms of lack of female participation have been well documented. However, there is little evidence about country-level female participation in cancer research. Methodology Through a complex filter, cancer research papers were identified and grouped by countries and sex of the first and last authors of each paper and analysed by the percentage of females in these positions alongside other parameters. Results Our analysis of 56 countries’ outputs, in 2009, revealed that females were the first authors in 37.2% and last authors in 23.3% of papers. In 2019, females were the first author in 41.6% and last author in 29.4% of papers. Females increased as first authors by 26%, and as last authors by 12% between these two time periods. The top performing countries in terms female/male parity for first or last authorship were in Eastern and Sou
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 2 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 2 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 3 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 1Nanomedicine in Oncology | BMJ Oncology - 3 month(s) ago
Submi ssion Open: 2nd October 2023 Submission Deadline: 29th March 2024 We are pleased to offer a 25% discount on the Article Processing Charge (APC) for articles submitted to this Topic Collection. Please visit our author hub for more information about the benefits of submitting to a Topic Collection. In the past few decades, significant progress has been made in the treatment and diagnosis of tumours. However, side effects, drug resistance and early-stage diagnosis remain challenges that will dampen
Source: bmjoncology.bmj.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending - 3 month(s) ago
In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs. All data relevant to the study are included in the article or uploaded as online supplemental information.
Source: bmjoncology.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending - 3 month(s) ago
In the field of general medicine, class effects, or therapeutic interchangeability, have been declared for several families of drugs including statins, calcium channel blockers and ACE inhibitors. The existence of such class effects enables healthcare payers to negotiate for substantially lower drug prices, thereby reducing financial toxicity, both at an individual and societal levels. Until now, the existence of class effects in oncology has been considered rare. Here, we review evidence from clinical trials that supports the existence of class effects for several types of anticancer drugs. These class effects in oncology should be exploited to reduce healthcare costs. All data relevant to the study are included in the article or uploaded as online supplemental information.
Source: bmjoncology.bmj.comCategories: General Medicine News, Hem/OncsTweet
Finally, don’t miss this important editorial by Kristina Jenei @kjmeetswrld https://t.co/rlaz7C5czi